Cardarine benefits

The single most consequential fact about Cardarine (GW-501516) is not its metabolic effects—it's that the compound was pulled from clinical development after reproducible animal data showed it accelerated cancer growth across multiple tissue types. That reality sits awkwardly beside its popularity in research circles interested in endurance and fat oxidation, which comes from a compelling set of rodent metabolic studies that preceded the safety signal. The compound's biological mechanism is legitimate; the risk profile is what changed the calculation.

How a Failed Drug Became a Research PPARδ Model

GW-501516 is a synthetic PPARδ agonist, not a SARM—despite being routinely grouped with selective androgen receptor modulators in fitness and research communities. It was developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s as part of an effort to target metabolic syndrome, dyslipidemia, and cardiovascular risk. The molecular structure is built around a thiazolyl and phenoxyacetic acid scaffold, designed for high selectivity toward PPARδ over the related PPARα and PPARγ isoforms.

PPARδ (peroxisome proliferator-activated receptor delta, also called PPARβ/δ) is a ligand-activated nuclear receptor that regulates gene transcription related to fatty acid metabolism, mitochondrial biogenesis, and inflammation. It is expressed at particularly high levels in skeletal muscle, heart, adipose tissue, and the brain. GSK's interest was in treating metabolic disease; the compound advanced through preclinical work and into Phase I and Phase II human trials by the mid-2000s before toxicology data forced a full stop.

The compound has a molecular formula of C₂₁H₁₈F₃NO₃S₂ and a molecular weight of 453.49 Da. It is lipophilic, orally bioavailable, and has demonstrated significant potency at low doses in animal models—all characteristics that made it an attractive drug candidate before the carcinogenicity issue emerged.

PPARδ Activation and the Metabolic Gene Switch

GW-501516 works by binding to PPARδ with high affinity and specificity. Once bound, PPARδ heterodimerizes with retinoid X receptor (RXR) and translocates to the nucleus, where the complex binds to peroxisome proliferator response elements (PPREs) on DNA. This binding activates transcription of genes involved in fatty acid oxidation, mitochondrial function, and energy homeostasis.

The downstream effects are concentrated in tissues with high PPARδ expression. In skeletal muscle, activation upregulates genes like carnitine palmitoyltransferase 1 (CPT1), which governs the transport of fatty acids into mitochondria for beta-oxidation, and uncoupling protein 3 (UCP3), which may influence thermogenesis and reduce reactive oxygen species. In adipose tissue, PPARδ activation shifts metabolism away from glucose utilization toward fat burning, and in macrophages, it appears to suppress inflammatory cytokine production.

One of the most consistent findings in rodent models is an increase in slow-twitch (type I) muscle fiber gene expression and mitochondrial density. PPARδ activation via GW-501516 appears to mimic aspects of endurance training at the transcriptional level—cells upregulate oxidative metabolism machinery even without exercise stimulus. This is not the same as building muscle tissue; it is a metabolic reprogramming that favors sustained energy output over glycolytic bursts.

In the liver, PPARδ activation can improve lipid handling and reduce circulating triglycerides, though hepatic PPARδ expression is lower than in muscle. The receptor's role in the brain is less well characterized, but rodent studies suggest involvement in neuroinflammation and possibly neurogenesis in the hippocampus.

What Rodent Endurance Studies Actually Showed—and What Human Trials Revealed Before Termination

The most widely cited Cardarine research comes from a 2007 paper in Cell Metabolism (Wang et al.) using sedentary and exercise-trained mice. Mice treated with GW-501516 for four weeks showed a dose-dependent increase in running time to exhaustion—up to 68% longer than controls in the sedentary group and 75% longer in the trained group. Muscle fiber analysis revealed increased expression of oxidative metabolism genes and a shift toward type I fiber characteristics. This was not anabolic in the testosterone sense; it was metabolic reprogramming.

Other rodent work demonstrated improvements in lipid profiles. Obese rhesus monkeys treated with GW-501516 showed increased HDL cholesterol, reduced triglycerides, and improved insulin sensitivity over 6–8 weeks, effects mediated by PPARδ's role in reverse cholesterol transport and hepatic lipid metabolism. These findings were consistent with the compound's original therapeutic target: metabolic syndrome.

In early-phase human trials conducted by GSK, short-term dosing (2.5–10 mg/day for 2–12 weeks) produced modest improvements in HDL levels and reductions in LDL and triglycerides in small cohorts of healthy volunteers and dyslipidemic patients. No serious adverse events were reported in these short trials, and oral bioavailability was confirmed. But the trials were terminated in 2007 after long-term rodent carcinogenicity studies revealed the safety issue.

The carcinogenicity data came from two-year studies in rats and mice at doses ranging from 3 to 40 mg/kg/day. Tumors developed in multiple tissues—colon, liver, bladder, stomach, skin, and tongue—in a dose-dependent manner across both species. Critically, tumor promotion occurred in nearly every organ system examined, not just one tissue type. The mechanism is thought to involve chronic PPARδ activation promoting cell proliferation and survival in pre-neoplastic cells, though the exact pathway remains debated. This was not a borderline signal; it was robust, reproducible, and multi-organ.

For research purposes only, GW-501516 remains available through chemical suppliers and is used in metabolic research, but it has no approved therapeutic use and is banned by the World Anti-Doping Agency (WADA) due to both safety concerns and performance-enhancement potential.

Research Dose Ranges, Half-Life, and Practical Considerations From the Literature

In published rodent studies, effective doses ranged from 2.5 to 10 mg/kg/day, typically administered orally. For a 70 kg human, this would scale to roughly 17.5 to 70 mg/day using simple body weight conversion, though allometric scaling would adjust this downward. The human trials that were completed used 2.5 to 10 mg/day as oral doses, with measurable lipid effects at the lower end.

GW-501516 has a half-life estimated at 12–24 hours in rodents based on pharmacokinetic studies, which supports once-daily dosing. It is lipophilic and absorbed well orally, with peak plasma concentrations occurring within 1–2 hours. The compound is metabolized primarily in the liver, and clearance appeared efficient in short-term human PK studies.

No significant drug-drug interactions were reported in the limited human data, but PPARδ activation could theoretically interact with drugs affecting lipid metabolism, insulin signaling, or mitochondrial function. Stability in solution is moderate; the compound degrades in the presence of light and oxidative conditions, so storage in dark, sealed containers at -20°C is standard in research settings.

The most critical research consideration is the carcinogenicity signal. Any work involving GW-501516 must account for the fact that chronic exposure accelerated tumor development in two species across multiple organs. There is no evidence that short-term exposure carries the same risk, but there is also no long-term human safety data. Regulatory agencies including the FDA and WADA have issued explicit warnings, and GSK has made clear it has no plans to resume development.

FAQ

Q: Is Cardarine actually a SARM?

No. Cardarine is a PPARδ agonist, not a selective androgen receptor modulator. It does not bind to androgen receptors and has no direct anabolic or androgenic effects. The confusion likely stems from its common grouping with SARMs in research and fitness contexts, where compounds with performance-related effects are often discussed together regardless of their molecular mechanism.

Q: Why did GlaxoSmithKline stop developing Cardarine?

Two-year carcinogenicity studies in rats and mice showed that GW-501516 caused tumors in multiple organs—colon, liver, bladder, stomach, skin, and tongue—at all doses tested. The effect was reproducible across species and dose-dependent, indicating a strong mechanistic link between chronic PPARδ activation and cancer promotion. GSK terminated all clinical trials in 2007 based on these findings.

Q: What did the human trials show before termination?

Short-term human trials (2–12 weeks, 2.5–10 mg/day) in healthy and dyslipidemic subjects showed modest increases in HDL cholesterol and reductions in LDL and triglycerides. No serious adverse events were reported, but these were early-phase studies with small sample sizes. No long-term human safety or efficacy data exists because the trials were stopped after the rodent carcinogenicity data emerged.

Q: Does GW-501516 cause cancer in humans?

There is no direct evidence of carcinogenicity in humans because no long-term studies have been conducted. The concern is extrapolated from consistent, reproducible tumor development in rodents across multiple tissue types with chronic dosing. The biological mechanism—PPARδ's role in cell proliferation and survival—is conserved across mammals, which increases the likelihood that the risk translates to humans, but no case reports or epidemiological data exist.

Q: What is the difference between PPARδ, PPARα, and PPARγ?

All three are nuclear receptors that regulate metabolism, but they have different tissue distributions and functions. PPARα (targeted by fibrates) is expressed mainly in liver and regulates fatty acid catabolism and ketogenesis. PPARγ (targeted by thiazolidinediones) is found in adipose tissue and regulates fat storage, insulin sensitivity, and inflammation. PPARδ is widely expressed in muscle and other tissues and primarily regulates fatty acid oxidation and endurance-related gene expression. GW-501516 is highly selective for PPARδ.

---

The content provided here is for informational and research purposes only. GW-501516 is not approved for human use and has been associated with serious safety concerns in animal models. Always consult a qualified healthcare provider before considering any experimental compounds.